Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II ramucirumab after lenvatinib in advanced hepatocellular carcinoma
jRCT1041190083Phase 2Recruiting
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab in hepatocellular carcinoma (HCC). Primary endpoint: Progression-free survival. Started Dec 2019; status: recruiting.
02
Drugs
ramucirumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT1041190083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041190083.